Effectiveness and safety of anti‐IL‐23 and anti‐IL‐17 biological therapies for psoriasis in elderly patients: Real‐world experience from two Italian hospitals

医学 银屑病 人口 内科学 皮肤病科 环境卫生
作者
Giovanni Fiorillo,Luciano Ibba,Luigi Gargiulo,Carlo Alberto Vignoli,A. Alfano,Andrea Cortese,Francesco Toso,Diego Orsini,Paolo Iacovelli,Pasquale Frascione,Alessandra Narcisi,Antonio Costanzo,Mario Valenti
出处
期刊:Journal of The European Academy of Dermatology and Venereology [Wiley]
卷期号:37 (12) 被引量:3
标识
DOI:10.1111/jdv.19355
摘要

Dear Editor, Psoriasis is a chronic inflammatory disease affecting 2%–4% of the general population worldwide.1-5 Due to the global increase in life expectancy, older patients with psoriasis constitute a growing group.2, 5 Conventional systemic drugs tend to be avoided in this subpopulation, due to the higher prevalence of comorbidities and drug interactions, whereas recurrent visits for phototherapy may not be suitable for patients with limited mobility or supported by caregivers.4 For these reasons, elderly patients with moderate-to-severe psoriasis are often undertreated.2-5 Few data are available on the use of interleukin (IL) inhibitors in the elderly, as they are often underrepresented in clinical trials.3-5 This study aimed to evaluate the effectiveness and safety of anti-IL-23 and anti-IL-17 biologics for psoriasis in over-65 patients. We collected data from two Italian hospitals' database records, including patients ≥65 years old receiving an anti-IL-23 or anti-IL-17 agent approved for psoriasis for at least 16 weeks. Eligibility for biological therapy was evaluated by using the Italian adaptation of EuroGuiDerm guideline.6 Patients with a cancer diagnosis within the previous 5 years were started on biologics because they had failed other treatments, after a discussion with the oncologist. We used Psoriasis Area and Severity Index (PASI) to assess severity at each visit. Effectiveness was evaluated by registering the percentages of patients that achieved an improvement of 75%, 90% and 100% in PASI (PASI75, PASI90 and PASI100, respectively) and that reached PASI ≤2. Safety was assessed by evaluating the rates of treatment discontinuation and the occurrence of adverse events (AEs) at each timepoint. Multivariate logistic regression was performed to identify predictors of response to different variables. A p-value of <0.05 was considered statistically significant. This study included 205 patients, with a mean age of 72.20 years (Standard Deviation [SD] 6.88). Of note, the patients ≥75 years old were 66 (32.20%). The characteristics of our population are summarized in Table 1. All patients completed 16 weeks of biological treatment, whereas 148 (72.20%) reached 52 weeks and 96 (46.83%) 104 weeks. The results concerning the effectiveness profile and multivariate analysis are shown in Figure 1. PASI 90 and 100 were achieved by 116 (78.38%) and 88 (59.46%) patients at week 52 and by 73 (76.04%) and 55 (57.29%) patients at week 104, respectively. At week 16, a higher PASI 75 response was observed in the bio-naïve subgroup (odds ratio [OR]: 3.13, 95% confidence interval [CI]: 1.19–8.22, p = 0.021) and a lower PASI90 response in patients with involvement of difficult-to-treat areas (OR: 0.28, 95% CI 0.10–0.74, p = 0.011). At week 104, we found that PASI90 response was significantly lower in the obese subgroup (OR: 0.15, 95% CI 0.02–0.94, p = 0.043). Regarding safety, biological treatment was discontinued in 30 patients, mainly due to relapses (13), followed by complete remissions (8), primary failures (6) and AEs (3). No severe AEs or new safety findings were detected. Patients affected by latent tuberculosis infection, viral hepatitis B and C did not develop disease reactivation. No new malignancies or recurrence/progression of previous cancer were found. Our study shows that IL-23 and IL-17 inhibitors were an effective treatment for psoriasis in a large cohort of elderly, also supporting their use in patients with cardiometabolic diseases, which are frequent in this subgroup.7 Despite the higher percentage of comorbidities, the most observed AEs were comparable to those reported in younger patients.3-5 As in previous studies,8-10 no signs of viral hepatitis or latent tuberculosis reactivation were observed, as well as no cancer recurrence/progression or newly diagnosed malignancies. Psoriasis management in older adults may be challenging because of individual factors and the scarce scientific recommendations.2, 4, 5 As our population gets older and the prevalence of psoriasis is increasing in the elderly, specific guidelines are needed to help increase clinician comfort when prescribing biological agents.2, 4 Our experience adds new evidence to the effectiveness and tolerability of anti-IL-23 and anti-IL-17 drugs in this subgroup; however, further studies are needed to evaluate the effectiveness and safety of the latest licensed biologics in older patients. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. M. Valenti has been a consultant and/or speaker for Sanofi, Leo Pharma, Eli Lilly, Novartis, Janssen, AbbVie, UCB-Pharma and Boehringer Ingelheim. A. Costanzo has served as an advisory board member and consultant and has received fees and speaker’s honoraria or has participated in clinical trials for Abbvie, Almirall, Biogen, Leo Pharma, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme, and UCB-Pharma. A. Narcisi has served on advisory boards and received honoraria for lectures and research grants from Almirall, Abbvie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi Genzyme, Amgen, and Boehringer Ingelheim. L. Gargiulo has been a consultant for Almirall. The other authors have nothing to declare. The patients in this manuscript have given written informed consent to publication of their case details. The data that support the findings of this study are available from the corresponding author upon reasonable request.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
渤哥完成签到,获得积分10
刚刚
桃博完成签到,获得积分10
刚刚
刚刚
小二郎的应助被Ari_Kun采纳,获得10
1秒前
梦欢完成签到,获得积分10
1秒前
留下记忆完成签到,获得积分10
2秒前
2秒前
3秒前
4秒前
4秒前
渤哥发布了新的文献求助10
4秒前
4秒前
5秒前
留下记忆发布了新的文献求助10
5秒前
5秒前
在水一方的应助被黎明采纳,获得10
6秒前
阳光的冷霜完成签到,获得积分10
7秒前
ml完成签到,获得积分10
8秒前
8秒前
zzz发布了新的文献求助10
8秒前
hxr发布了新的文献求助10
8秒前
三告发布了新的文献求助10
8秒前
Fu发布了新的文献求助10
8秒前
9秒前
wwwying完成签到,获得积分10
9秒前
10秒前
美满夏寒发布了新的文献求助10
10秒前
10秒前
寻欢完成签到,获得积分10
11秒前
猫不理解完成签到,获得积分20
11秒前
比山稳发布了新的文献求助10
12秒前
Lucas的应助被lyj采纳,获得10
12秒前
12秒前
酷波er的应助被优秀的荔枝采纳,获得10
13秒前
顾矜的应助被桃博采纳,获得10
13秒前
科研通AI6.3的应助被红雨灰衣采纳,获得10
13秒前
14秒前
14秒前
14秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177849
求助须知:如何正确求助?哪些是违规求助? 9568641
关于积分的说明 21800145
捐赠科研通 7772473
什么是DOI,文献DOI怎么找? 3432537
关于科研通互助平台的介绍 2556720
邀请新用户注册赠送积分活动 2478067